Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease

Kazuo Abe; Mayako Takanashi; Takehiko Yanagihara; Sabro Sakoda

doi:10.1155/2002/473140

Behavioural Neurology (Jan 2002)

Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease

Kazuo Abe,
Mayako Takanashi,
Takehiko Yanagihara,
Sabro Sakoda

Affiliations

Kazuo Abe: Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
Mayako Takanashi: Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
Takehiko Yanagihara: Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
Sabro Sakoda: Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan

DOI: https://doi.org/10.1155/2002/473140
Journal volume & issue: Vol. 13, no. 3-4
pp. 117 – 121

Abstract

Read online

Objectives: Fatigue is a complaint frequently encountered among patients with Parkinson’s disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD.

Published in Behavioural Neurology

ISSN: 0953-4180 (Print); 1875-8584 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://onlinelibrary.wiley.com/journal/3037

About the journal